|Day Low/High||1.93 / 1.95|
|52 Wk Low/High||1.40 / 7.12|
Conference Call and Webcast Presentation at 8:00 a.m. ET Today
Late Breaker Oral Presentation Tomorrow to Detail Phase 2 Liver Cirrhosis Trial 3-month Results
Focusing on Initial Registration in NASH Cirrhosis With Parallel Development in NASH Fibrosis
Adding Long-term Safety Data to Support Initial Registration of Emricasan in Cirrhosis
Conatus Pharmaceuticals (CNAT) stock is increasing in mid-morning trading on Wednesday after the company said a Phase 2 trial of its liver drug showed positive results.
Conatus Pharmaceuticals (CNAT) shares are up over 10% on strong phase 2 test data of its hypertension treatment candidate.